Goldman Sachs has made another big hire, this time securing Graig Suvannavejh as an executive director and Senior equity research analyst. In particular, Suvannavejh will be following the European biotechnology sector.
The addition of Suvannavejh comes at a time when the is bolstering its research team. This is in reaction to the new regulatory framework in the European Union (EU) thanks to MiFID II.
Under the new regulation, big investment banks are seeking senior research specialists in the hope it will increase revenues. Suvannavejh fits the model to a tee, as he has extensive experience as an equity research analyst, with a focus on biotechnology and pharmaceuticals. He joined the firm earlier this month and is based in its London office.
Graig Suvannavejh’s experience before Goldman Sachs
Prior to working at Goldman Sachs, Suvannavejh has worked at a number of big-name investment banks. In 2000, he began his career as an analyst at . In addition, he has held the position of Director at UBS, Vice President at global investment banking firm and was also employed by CIBC Capital Markets.
Source: LinkedIn
Before that, between April 2016 up until February 2017, Suvannavejh worked in Corporate Development and Investor Relations at Alzheon, Inc., an Alzheimer research clinic. In this role, he helped with the revision of the company’s overall financial and clinical strategies. He also helped to maintain and expand relationships with buy-side institutional investors, sell-side biotechnology analysts and investment bankers.
Throughout his career, Suvannavejh has also worked as an Associate Director at Biogen Idec, Senior Analyst at MLV & Co. and a Managing Partner at Axon Healthcare Partners. Between 1988 to 1993, he studied at Georgetown University. In 1992 he graduated with a Bachelor of Science in Biology and in 1993 he completed his Master of Science for Biology. Suvannavejh then went on to earn a PhD in Neuroscience from Northwestern University, graduating with the qualification in 2000.
Be First to Comment